Filter paper cards may simplify bluetongue virus surveillance

CURRENT FULL VERSION: A newly published study from Argentina suggests bluetongue virus surveillance may become easier to carry out far from centralized diagnostic labs. Writing in Veterinary Sciences, researchers described a filter paper card method for collecting, preserving, and transporting blood samples for bluetongue virus RT-qPCR testing, with the goal of reducing the logistical burden of moving refrigerated blood over long distances. (pubmed.ncbi.nlm.nih.gov)

That matters because bluetongue surveillance still depends on laboratory confirmation, while access to testing infrastructure is uneven. The study authors note that in Argentina, diagnostic capacity is concentrated in a limited number of laboratories, including some located far from the main sample collection areas. WOAH also emphasizes that suspected bluetongue cases identified through clinical surveillance should be confirmed by lab testing, underscoring the importance of sample integrity from field collection through analysis. (pubmed.ncbi.nlm.nih.gov)

In the study, the team optimized a protocol for drying blood on filter paper cards and later recovering viral RNA for RT-qPCR. According to the abstract indexed by PubMed, hydration with TE at 37 °C produced the lowest Cq values among the tested conditions. The researchers reported that about 10 TCID50/mL was the lowest viral concentration consistently detected under their experimental setup. They then evaluated storage at 25 °C, 4 °C, -20 °C, and -80 °C over intervals ranging from 1 day to 360 days, and found sample stability was maintained through 120 days at all tested temperatures. (pubmed.ncbi.nlm.nih.gov)

The field component is especially relevant for practicing veterinarians and surveillance teams. The authors collected paired samples from cattle and sheep, using both conventional tubes and filter paper cards, and found nearly perfect agreement between the two methods by Cohen’s kappa. They also reported an absence of infectious material in the card eluate, a point that could be important for biosafety and shipping workflows if the findings hold up in broader use. The preprint version adds context that the work was designed to support safer, simpler transport from remote collection points. (pubmed.ncbi.nlm.nih.gov)

There doesn’t appear to be substantial outside commentary on this specific paper yet, but the broader concept is well grounded. Prior veterinary and wildlife disease research has shown that dried blood spot or filter paper approaches can support surveillance when refrigeration is difficult, including earlier bluetongue-related serologic work and more recent studies highlighting the usefulness of filter paper-preserved blood in remote settings. That doesn’t prove interchangeability across every assay, but it does support the study’s central premise that simplified sampling can expand surveillance reach. (pubmed.ncbi.nlm.nih.gov)

The broader bluetongue control context also helps explain why surveillance logistics still matter. A recent Veterinary Sciences review on bluetongue antigenicity and vaccine strategies describes active work across inactivated, live attenuated, virus-like particle, viral-vectored, subunit, DISC, and DISA vaccine platforms. But it also notes persistent limitations: many next-generation candidates trade some immunogenicity for better safety or DIVA compatibility, most remain largely serotype-specific, and many have been studied more in mice than in natural target species, with relatively limited field validation. In practice, that means vaccination remains essential but does not eliminate the need for dependable field surveillance and laboratory confirmation.

Why it matters: For veterinary professionals, the practical value is less about a new assay than about a new workflow. Bluetongue often creates costs through surveillance, testing, movement controls, and trade consequences, even when clinical disease is limited. If blood on filter paper cards can be collected in the field, shipped without a strict cold chain, and still perform reliably in RT-qPCR, that could lower barriers to routine monitoring in cattle and sheep populations, especially in regions where bluetongue is exotic, emerging, or geographically patchy. It may also help public and private veterinary networks expand sampling coverage without proportionally expanding transport complexity. That could be particularly useful while bluetongue control continues to rely on vaccines that, according to recent reviews, still face challenges around breadth of protection, target-species validation, and balancing safety with strong immunity. (woah.org)

There are still caveats. The published abstract describes the field evaluation as preliminary, so veterinary diagnosticians will likely want larger validation datasets, clearer performance metrics across viral loads, and operational details such as humidity tolerance, shipping conditions, and compatibility with different lab extraction workflows before adopting the method widely. Those questions are typical for field-deployable sample collection systems, and they’ll likely determine whether the protocol remains a promising research tool or becomes part of routine surveillance practice. Similar caution applies more broadly in bluetongue control: recent vaccine reviews emphasize the need for more target-species testing and broader protection across serotypes before newer platforms can fully close surveillance gaps. This is an inference based on the study’s preliminary framing and on known implementation needs for diagnostic workflows. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is likely external validation, either through larger national surveillance programs or by other laboratories testing the protocol under real shipping conditions; if those data are positive, filter paper card collection could become a useful addition to bluetongue surveillance programs in remote and resource-constrained settings. It will also be worth watching whether improved sampling workflows are paired with evolving vaccine strategies, including efforts to target more conserved antigens and broaden protection across serotypes. (pubmed.ncbi.nlm.nih.gov)